作者: Paul M O’Byrne
DOI: 10.1155/2013/183948
关键词: Asthma therapy 、 Severity of illness 、 Population 、 Antibody 、 Monoclonal antibody 、 Asthma 、 Immunology 、 Refractory asthma 、 Antibodies monoclonal 、 Medicine
摘要: BACKGROUND: Patients with severe refractory asthma represent a small subset of the asthmatic population (between 5% and 10% all patients) but are greatest burden to health care system. New treatment approaches developed manage some phenotypes have included humanized monoclonal antibodies (hMabs).